| Autor: |
Rohit Gupta, Robert P. Baughman, Steven D. Nathan, Athol U. Wells, Vasilis Kouranos, Esam H. Alhamad, Daniel A. Culver, Joseph Barney, Eva M. Carmona, Francis C. Cordova, Marloes Huitema, Mary Beth Scholand, Marlies Wijsenbeek, Sivagini Ganesh, Surinder S. Birring, Laura C. Price, Stephen John Wort, Oksana A. Shlobin |
| Přispěvatelé: |
Pulmonary Medicine |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Respiratory Medicine, 196:106801. W.B. Saunders |
| ISSN: |
0954-6111 |
| DOI: |
10.1016/j.rmed.2022.106801 |
| Popis: |
Introduction: Sarcoidosis associated pulmonary hypertension (SAPH) is a leading contributor to sarcoidosis-related mortality. The 6-min walk test (6MWT) is widely used in assessment of cardiorespiratory conditions. A reduced 6-min walk distance (6MWD) has been associated with increased mortality in SAPH. We examined patients from the Registry of Sarcoidosis Associated Pulmonary Hypertension (ReSAPH) who had performed 6MWT at enrollment to identify variables that affect 6MWD, and the prognostic value of 6MWT variables regarding death or lung transplantation. Material and methods: ReSAPH patients with available 6MWT were included. Variables analyzed using pre-defined cutoffs included 6MWD, initial and end of test Borg dyspnea score, oxygen saturation, and heart rate at beginning, end, and after 1-min recovery, absolute change in oxygen saturation, modified distance-saturation product (mDSP), and the heart rate recovery at 1-min (HRR). Findings: 174 patients met inclusion criteria; 48 patients died and 8 underwent lung transplantation. Patients with 6MWD300 m (p = 0.012). No associations with outcome were observed with mDSP cutoff 200 m%, desaturation≥5% and oxygen saturation |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect